TapImmune Inc (TPIV) (TPIV.OB) Stuck at $0.49/share Despite Spam

We have received another TapImmune Inc (TPIV) (TPIV.OB) stock spam at Windows Live Hotmail (junk box). This one is obviously intended for the start of the trading week on Monday. So, after TPIV trading volume dropped nearly 60% on Thursday, it jumped back to over 100,000 shares traded on Friday, but again, as we said in our last post covering TapImmune (TPIV), the absolute dollar value traded is insignificant, as is the volume compared to shares outstanding (36.78 million). Interestingly TapImmune (TPIV) did trade as high as $0.52/share on Friday (its low was $0.47/share), but it closed again at $0.49. Pay close attention to the "Shorrt Term Tarrget: $1.25 Lonng Term Tarrget: $4.30".

Details of the TapImmune Inc (TPIV) (TPIV.OB) stock spam:

"Company Market news‏"

Follow the money.

Bill Gates announced that he was donating $10billion to
help develop vaccines for children. Where exactly does
this money go? Well in 1997 and 2007 hundreds of
millions went to The Aeras Global TB Vaccine Foundation.
This time around Uncle Gates will also be smiling on the
foundation.

The story today, however, is about TapImmune Inc.

TapImmune Inc. announced that it has signed a Letter of
Intent (LOI) with Aeras Global TB Vaccine Foundation to
enter into an R&D collaboration effort. The overall goal of
this collaboration will be to evaluate the efficacy of TAP in
concert with novel vaccine vectors encoding TB
immunogens under development at Aeras with the aim of
advancing suitable candidates to clinical development.
Aeras will conduct all pre-clinical development studies.

TapImmune Inc.

Siymbol: TPIV

value: $0.49
Shorrt Term Tarrget: $1.25
Lonng Term Tarrget: $4.30

TapImmune Inc. is a biotechnology company specializing
in the development of innovative cell based
immunotherapeutics. The Company's lead product
candidate, the AdhTAP vaccine enhancer is designed to
restore and augment antigen presentation and
subsequent recognition and killing of cancer cells by the
immune system.

The Company is developing a TAP based prophylactic
vaccine which initial tests indicate may increase the
efficacy of targeted prophylactic vaccines by up to 1000
times.

All eyes are going to be on this Winner with a major
Awareness campaign shifting into top gear. Keep it on
your radar!

Afterward the staff prepared a report detailing the techniques used on Anderson including ammonia

capsules under his nose knee strikes a straight arm-bar takedown bending his wrist and pouring water over his head
To explain the use of force one staff member wrote I ordered (the) offender
to stop resisting and relax his arms Offender refused to comply with those instructions Some experts on juvenile justice call it excessive force But the sheriffs office said Anderson was restrained for being uncooperative After the incident he was taken away on a stretcher and died later that day Andersons family accused the employees of killing the teen and demanded an independent
investigation
The charging document filed by Ober in Bay County Circuit Court identifies the eight charged as Henry Dickens Charles Enfinger Patrick Garrett Raymond Hauck Charles Helms Jr Henry McFadden Jr Kristin Smith and Joseph Walsh II They are described as being caregivers of Martin Lee Anderson who caused his death

TapImmune Inc (TPIV) (TPIV.OB) Up 6.5%, Fueled by Stock Spam?

We have received a stock spam at Windows Live Hotmail concerning TapImmune Inc (TPIV) (TPIV.OB). TapImmune (TPIV) gained 6.52% to $0.49/share on volume of 126,675. It opened a penny higher at $0.47 and traded between its open and closing quotes. TPIV has a market cap of $18.02 million. With 36.78 million shares outstanding, volume was slightly higher than it has been on average, but is insignificant considering the absolute dollar value traded. The TapImmune spam did appear to give TPIV trading a boost since Wednesday's volume was 43,334. Volume on Tuesday was 100,600. Details of the TPIV spam follow, with the formatting the same as the original email. Notice the spelling of 'target' ("tarrget") consistent with many stock spams and the irrelevant text at the very bottom of the message.

TapImmune Inc (TPIV) (TPIV.OB)

"SmallCap secrets‏"

Health Care and BioMed Continue to Reap the Rewards!

Emerging Biomed companies are the place to be.
With the proper product and audience the returns can be out this world.
We would like to show you just such a company.

TapImmune Inc.

Syimbol: TPIV

Currrent Value: $0.46
Shorrt Term Tarrget: $1.25
Lonng Term Tarrget: $4.30

TapImmune Inc. is a biotechnology company specializing
in the development of innovative cell based immunotherapeutics
and vaccines in the areas of cancer and infectious disease.
The Company's lead product candidate, the AdhTAP vaccine enhancer
is designed to restore and augment antigen presentation and subsequent
recognition and killing of cancer cells by the immune system.

The Company is also developing a TAP based prophylactic vaccine
which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times.

All eyes are going to be on this Winner with a Major Awareness campaign shifting into top gear.

Keep it on your radar!

In his first official act Benedict visited the mausoleum of Mustafa Kemal Ataturk the

founder of modern Turkey In a guest book he wrote that Turkey is a meeting point of different religions and cultures and a bridge between Asia and Europe

Later Tuesday while addressing Turkeys diplomatic corps the pope heralded the countrys

role in the UN peacekeeping force in southern Lebanon